A prospective study on the result of surgical excision and adjuvant irradiation for therapy-resistant keloids was conducted by van de Kar et al. (Plast. Reconstr. Surg. 119: 2248, 2007). This approach to keloids follows the International Clinical Recommendations on Scar Management based on retrospective studies that do not define recurrence. Moreover, the significant variations in methodology of most of the studies is well highlighted; many of them, being retrospective, refer to a treatment that is not standardized, and inclusion/exclusion criteria were set afterward (subjecting the study to bias), making it difficult to compare results. What is really clear is that there is still no consensus on the optimal treatment of keloids. After a mean follow-up of 19 months, van de Kar et al. had a cure rate of 28 percent, compared with the 78 percent average of previous studies. They ascribed their low rate to the “long” follow-up and the strict inclusion criteria of their study.
A few other considerations are necessary. Radiation therapy, commonly used for malignancy, has both acute and chronic effects on the skin. Acute effects include erythema, inflammation, edema, desquamation, and ulceration. Late effects include change in pigmentation, atrophy of the epithelium and dermis, decreased local vascularity associated with fibrosis, teleangiectasia, sebaceous and sweat gland dysfunction, necrosis, and, above all, neoplasia.1 The late effects are challenging to treat; treatment ranges from simple intervention, such as protection of hypopigmented areas, to grafting or flaps (local or microvascular) for tumors.
Many epidemiological studies have demonstrated that ionizing radiation carries a risk of carcinogenesis. Radiotherapy for the treatment of keloids was first introduced in 1906,2 yet 101 years later there is still debate about its safety. The optimal dosage schedule for radiotherapy is unclear, since authors disagree about total dose, fractionation, the time interval between surgery and radiotherapy, and whether electrons are preferable to photons. A number of large studies report a 0 percent carcinogenicity rate, although there is some concern regarding length of follow-up as short as 2 years.3
A review of the literature shows that, despite the potential risks, very few malignancies arise from treating keloids with radiotherapy after 8 years (keloid on thyroid), 23 years (keloid on breast and lung), and 30 years (keloid on breast).4–6
New retrospective or, better, prospective studies (with a new pinpoint schedule) should focus on the effect of combined surgical excision and immediate postoperative adjuvant irradiation, looking at the long-term follow-up (up to 30 years) of the use of radiation as a therapeutic modality to control keloids with respect to the precept of primum non nocere. Regardless, radiation should always be prohibited in children, young adults, pregnant women, and patients with keloids close to the thyroid or breast. In the meantime, in strictly selected cases, when other treatments (such as steroids, pressure therapy, silicone gel sheeting, laser therapy, and previous surgery) have failed, we agree with literature reports that advocate radiotherapy as the mainstay of treatment.
Luigi Annacontini, M.D.
Domenico Parisi, M.D.
Arianna Maiorella, M.D.
Antonella Campanale, M.D.
Giuseppe Gozzo, M.D.
Aurelio Portincasa, M.D.
Department of Plastic and Reconstructive Surgery
University of Foggia
1. Mustoe, T. A., and Porras-Reyes, B. H. Modulation of wound healing in chronic irradiated tissues. Clin. Plast. Surg.
20: 465, 1993.
2. De Bearman, R., and Gougerot, H. Cheloides des maqueuses. Ann. Dermatol. Syphilol. (Paris)
7: 151, 1906.
3. Borok, T. L., Bray, M., Sinclair, I., Plafker, J., LaBirth, L., and Rollins, M. D. Role of ionizing irradiation for 393 keloids. J. Radiat. Oncol. Biol. Phys.
15: 865, 1988.
4. Botwood, N., Lewanski, C., and Lowdell, C. The risk of treating keloids with radiotherapy. Br. J. Radiol.
72: 1222, 1999.
5. Hoffman, S. Radiotherapy for keloids. Ann. Plast. Surg.
9: 265, 1982.
6. Bilbey, J. H., Muller, N. L., Miller, R. R., and Nelemus, B. Localized fibrous mesothelioma of pleura following external ionizing radiation therapy. Chest
94: 1291, 1988.
Letters to the Editor, discussing material recently published in the Journal, are welcome. They will have the best chance of acceptance if they are received within 8 weeks of an article’s publication. Letters to the Editor may be published with a response from the authors of the article being discussed. Discussions beyond the initial letter and response will not be published. Letters submitted pertaining to published Discussions of articles will not be printed. Letters to the Editor are not usually peer reviewed, but the Journal may invite replies from the authors of the original publication. All Letters are published at the discretion of the Editor.
Authors will be listed in the order in which they appear in the submission. Letters should be submitted electronically via PRS’ enkwell, at www.editorialmanager.com/prs/.
We reserve the right to edit Letters to meet requirements of space and format. Any financial interests relevant to the content of the correspondence must be disclosed. Submission of a Letter constitutes permission for the American Society of Plastic Surgeons and its licensees and asignees to publish it in the Journal and in any other form or medium.
The views, opinions, and conclusions expressed in the Letters to the Editor represent the personal opinions of the individual writers and not those of the publisher, the Editorial Board, or the sponsors of the Journal. Any stated views, opinions, and conclusions do not reflect the policy of any of the sponsoring organizations or of the institutions with which the writer is affiliated, and the publisher, the Editorial Board, and the sponsoring organizations assume no responsibility for the content of such correspondence.